Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorBolat, Zeynep Busra
dc.contributor.authorNezir, Ayca Ece
dc.contributor.authorDevrim, Burcu
dc.contributor.authorZemheri, Ebru
dc.contributor.authorGulyuz, Sevgi
dc.contributor.authorOzkose, Umut Ugur
dc.contributor.authorBozkir, Asuman
dc.contributor.authorTelci, Dilek
dc.contributor.authorSahin, Fikrettin
dc.date.accessioned2021-10-04T06:29:20Z
dc.date.available2021-10-04T06:29:20Z
dc.date.issued2021en_US
dc.identifier.citationBolat, Z. B., Nezir, A. E., Devrim, B., Zemheri, E., Gulyuz, S., Ozkose, U. U., ... & Sahin, F. (2021). Delivery of doxorubicin loaded P18 conjugated-poly (2-ethyl-oxazoline)-DOPE nanoliposomes for targeted therapy of breast cancer. Toxicology and Applied Pharmacology, 428, 115671, p.1-10.en_US
dc.identifier.issn0041-008X
dc.identifier.urihttps://hdl.handle.net/20.500.12960/1279
dc.description.abstractBreast cancer, a heterogeneous disease, has the highest incidence rate and is a major cause of death in females worldwide. Drug delivery by using nanotechnology has shown great promise for improving cancer treatment. Nanoliposomes are known to have enhanced accumulation ability in tumors due to prolonged systemic circulation. Peptide 18 (P18), a tumor homing peptide targeting keratin-1 (KRT-1), was previously shown to have high binding affinity towards breast cancer cells. In this study, we investigate the ability of P18 conjugated PEtOxDOPE nanoliposomes (P18-PEtOx-DOPE) for the targeted delivery of doxorubicin to AU565 breast cancer model. Toxicology studies of PEtOx-DOPE nanoliposomes performed on normal breast epithelial cells (MCF10A), showed minimal toxicity. Doxorubicin delivery by P18-PEtOx-DOPE to AU565 cells induces cytotoxicity in a dose and time dependent manner causing mitotic arrest in G2/M phase at 24 h. Anti-cancer activity of P18-PEtOxDOPE-DOX nanoliposomes on AU565 cells was detected by Annexin V/PI apoptosis assay. In terms of in vivo antitumor efficacy, P18-PEtOx-DOPE-DOX nanoliposomes administration to AU565 CD-1 nu/nu mice model showed significant decrease in tumor volume suggesting that DOX delivered by these nanoliposomes elicited a strong antitumor response comparable to the free delivery of doxorubicin. Overall, our results offered preclinical proof for the use of P18-PEtOx-DOPE-DOX nanoliposomes in KRT-1+ breast cancer therapy.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.ispartofToxicology and Applied Pharmacologyen_US
dc.relation.isversionof10.1016/j.taap.2021.115671en_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectBreast canceren_US
dc.subjectDoxorubicinen_US
dc.subjectDrug Deliveryen_US
dc.subjectNanoliposomesen_US
dc.subjectPeptide 18en_US
dc.subjectTargeted therapyen_US
dc.titleDelivery of doxorubicin loaded P18 conjugated-poly (2-ethyl-oxazoline)-DOPE nanoliposomes for targeted therapy of breast canceren_US
dc.typearticleen_US
dc.departmentFen Edebiyat Fakültesi, Kimya Bölümüen_US
dc.contributor.institutionauthorÖzköse, Umut Uğur
dc.identifier.volume428en_US
dc.identifier.issue115671en_US
dc.identifier.startpage1en_US
dc.identifier.endpage10en_US
dc.relation.tubitak213M726
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster